Focused on PhIII, BeiGene touts early PD-1 results; Amgen partners with Simcere on China biosimilars work
→ Hustling as fast as it can, BeiGene $BGNE today offered an early look at early-stage data for its PD-1 checkpoint partnered with Celgene $CELG. The company says it got the initial tumor responses it was looking for — with no dose-limiting toxicity — as researchers pursue two registration studies for BGB-A317 in urothelial cancer and classical Hodgkin lymphoma. The China-based biotech has a slate of Phase III studies in the pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.